Search

Empagliflozin

in 2014. … Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart

Garadacimab

[L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan. … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.

Dihydrocodeine

It was marketed in 1911. … It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis

Aminolevulinic acid

A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]

Brilliant blue G

Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures. … It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]

Vericiguat

[L31178] Although not the first sGC stimulator to be granted FDA approval ([riociguat] was approved in 2013 for use in pulmonary hypertension),[L3955] vericiguat is unique amongst its peers in that modifications … [L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure.

DL-alpha tocopheryl acetate

Sparsentan

[A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural elements of [irbesartan], an AT₁R antagonist, and biphenylsulfonamide, an ET<sub … Sparsentan is a dual antagonist of the endothelin type A receptor (ET_AR) and the angiotensin II (Ang II) type 1 receptor (AT₁R) with a similar affinity for both (9.3 nM for ET<sub

Human papillomavirus type 52 L1 capsid protein antigen

It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles … Human papillomavirus type 52L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.

Cetalkonium

Cetalkonium is a C16 alkyl benzalkonium chloride derivative with an amphipathic property which allows it to be used in different types of formulations. … [L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]